

Bradykinin-induced transient accumulation of inositol trisphosphate in neuron-like cell line NG108-15 cells

Koh Yano, Haruhiro Higashida*, Hiroaki Hattori and Yoshinori Nozawa

*Department of Biochemistry, Gifu University School of Medicine, Tsukasamachi-40, Gifu 500, and *Department of Pharmacology, Cancer Research Institute, Kanazawa University, 13-1 Takaramachi, Kanazawa 920, Japan*

Received 4 January 1985

Studies were undertaken to further elucidate the mechanism(s) by which bradykinin-dependent phosphoinositide metabolism takes place in neuroblastoma $\times$ glioma hybrid NG108-15 cells [(1984) J. Biol. Chem. 259, 10201–10207] using [^3H]inositol-labelled cells. Bradykinin produced net increases in the level of [^3H]inositol phosphates, especially of [^3H]inositol trisphosphate which is formed transiently and most rapidly. The results indicate that bradykinin activates a phosphodiesterase to break down phosphatidylinositol 4,5-bisphosphate, generating two recently recognized intracellular messengers, 1,2-diacylglycerol and inositol trisphosphate.

Neuroblastoma $\times$ glioma Bradykinin Inositol trisphosphate Phosphodiesterase

1. INTRODUCTION

In many cell systems, Ca^{2+} -mobilising hormones and neurotransmitters can cause a rapid breakdown of PIP_2 through activation of a phosphodiesterase [1]. It has become increasingly apparent that the products of the phosphodiesteratic hydrolysis of PIP_2 may serve as intermediates in the transmembrane signalling [1]: 1,2-diacylglycerol activates protein kinase C [2] and (1,4,5) IP_3 acts as a mobiliser of intracellular Ca^{2+} [3–9]. These two putative second messengers are thought to synergistically activate the cells to carry out their physiological functions [10,11].

A previous report from our laboratory [12] showed that bradykinin induces a rapid loss of radioactivity from PIP_2 , independently of a rise in intracellular Ca^{2+} concentration, in $^{32}\text{P}_i$ -labelled neuroblastoma $\times$ glioma hybrid NG108-15 cells.

However, because of the multiple pathways in which phosphoinositides are metabolized [13], studies using ^{32}P labelling were unable to lead us to the conclusion as to the enzyme(s) which causes the loss of PIP_2 .

The aim here, therefore, is to establish the metabolic pathway by which PIP_2 is hydrolyzed in the bradykinin-stimulated NG108-15 cells. To achieve this, we have studied the effects of bradykinin on the accumulation of [^3H]inositol phosphates in the hybrid cells prelabelled with [^3H]inositol. The results show that bradykinin rapidly enhances the level IP_3 which is subsequently degraded to IP_2 and further to IP . Here, we can conclude that the bradykinin-induced PIP_2 breakdown in NG108-15 cells is due to activation of a phosphodiesterase.

2. MATERIALS AND METHODS

2.1. Cell culture

NG108-15 cells were cultured essentially as described previously [14,15].

Abbreviations: IP_3 , inositol trisphosphate; (1,4,5) IP_3 , inositol 1,4,5-trisphosphate; IP_2 , inositol bisphosphate; IP , inositol monophosphate; PIP_2 , phosphatidylinositol 4,5-bisphosphate

2.2. Studies with [^3H]inositol-labelled cells

NG108-15 cells which had been grown for 6 days in monolayer cultures were released from culture dishes with a rubber policeman. The harvested cells were washed once with Tris-buffered saline (TBS) consisting of 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl_2 , 0.8 mM MgSO_4 and 25 mM glucose. The washed cells (3×10^7 cells) were then incubated in 20 ml of the same buffer supplemented with 120 μCi of [^3H]inositol (Amersham) at 37°C. After 2.5 h, the medium was replaced with 20 ml of fresh TBS with no inositol and further incubated for 1 h. The labelled cells were washed two times with TBS and finally suspended in TBS containing 10 mM LiCl at a final concentration of 4×10^6 cells/ml. The inclusion of LiCl was to inhibit IP phosphatase [16,17]. Aliquots (0.25 ml) of the cell suspension were transferred to siliconized tubes and after 5 min preincubation at 37°C, bradykinin (Protein Research Foundation, Osaka) solution (0.05 ml) was added to give a final concentration of 1×10^{-5} M. For control incubations, the same volume of vehicle (TBS) alone was always added. At designated times, the reaction was terminated by the addition of 0.1 ml of 10% (w/v) perchloric acid [18]. The acid-soluble extract was neutralized with 0.15 ml of 1.53 M KOH-75 mM Hepes, and perchloric acid was precipitated on ice and removed by a brief centrifugation. The aqueous extract was then diluted to 5 ml with distilled water and was applied to a column (0.6 $\times$ 4.0 cm) of AG-1 $\times$ 2, 200-400 mesh (Bio-Rad), which had been converted to formate form. After free inositol and glycerophosphoinositol were eluted with 16 ml of 5 mM sodium tetraborate/60 mM ammonium formate, total inositol phosphates were eluted with 12 ml of 1.0 M ammonium formate/0.1 M formic acid, or individual inositol phosphates were eluted sequentially using 16 ml of 0.2 M ammonium formate/0.1 M formic acid for IP, 20 ml of 0.4 M ammonium formate/0.1 M formic acid for IP_2 , and 12 ml of 1.0 M ammonium formate/0.1 M formic acid for IP_3 as described by Berridge et al. [19]. Radioactivity in each fraction was counted with a Beckman liquid scintillation counter, LS 7500 model, in the gel phase using 60% (v/v) Aquasol (New England Nuclear) [20]. Usually, 4-ml samples of the eluates were collected and mixed with Aquasol. In the case of 1.0 M ammonium formate/0.1 M formic acid

eluates, however, 2-ml samples were diluted to 4 ml with distilled water and then Aquasol was added so that the gel phase can be formed.

2.3. Expression of data

Data in table 1 and fig.1 are expressed as the mean $\pm$ SE of 4 samples from two experiments, each performed in duplicate.

3. RESULTS AND DISCUSSION

The effect of bradykinin on the level of [^3H]inositol phosphates is presented in table 1. Bradykinin caused an increase in [^3H]inositol phosphates to 3.1-fold of control at 5 min. This finding indicates that bradykinin is capable of activating phosphodiesterase(s) which degrades phosphoinositides.

In order to determine the primary substrate of the bradykinin-stimulated phosphoinositide breakdown, the time course of the effect of bradykinin on the release of individual inositol phosphates was examined. As shown in fig.1, the addition of bradykinin to [^3H]inositol-labelled cells induced a rapid occurrence of IP_3 , which reached a peak (3.4-fold increase of control) at 10 s. There was a subsequent accumulation of IP_2 and it was maximally enhanced by 3.5-fold at 30 s. The levels of these two inositol phosphates then gradually declined and returned to near-control levels by 5 min. The increase of IP level, in contrast, was small at the onset but became greater with an incubation time up to 5 min. This time sequential generation of inositol phosphates in the order of IP_3 , IP_2 and IP, taken together with the previous observation [12] that bradykinin causes a preferential loss of ^{32}P -PIP $_2$ from prelabelled cells, in-

Table 1

Bradykinin-stimulated increase in the content of total inositol phosphates

	Control	Bradykinin
[^3H]Inositol phosphates (dpm/ 10^6 cells)	1249 $\pm$ 265	3918 $\pm$ 318

[^3H]Inositol-labelled NG108-15 cells were incubated at 37°C for 5 min with or without 1×10^{-5} M bradykinin. Total inositol phosphates were separated as described in section 2




Fig.1. Time course of the effect of bradykinin on the production of individual inositol phosphates in [³H]inositol-labelled NG108-15 cells. [³H]inositol-labelled NG108-15 cells were incubated at 37°C for 5 min with or without 1×10^{-5} M bradykinin. The individual inositol phosphates were separated as described in section 2. Data are expressed as percentages of their respective controls. Control values at zero time for [³H]IP₃, [³H]IP₂ and [³H]IP (dpm/10⁶ cells) were 156 ± 47 , 369 ± 74 and 660 ± 48 , respectively.

indicates that the primary substrate of the bradykinin-activated phosphodiesterase is PIP₂. The increase in the content of IP₂ and IP, therefore, is most likely to be the result of the sequential degradation of IP₃ to IP₂ and IP₂ to IP by their respective phosphatases [19,21,22]. However, the possibility of phosphatidylinositol 4-phosphate breakdown to yield IP₂ cannot be excluded.

The results obtained here demonstrate that bradykinin-receptor interaction in NG108-15 cells can produce two putative second messengers, IP₃ and 1,2-diacylglycerol by a stimulated phosphodiesteratic hydrolysis of PIP₂. Diacylglycerol is thought to play a pivotal role in cell activation by phosphorylating target protein(s) through protein kinase C [11], and IP₃ by releasing Ca²⁺ from internal store(s) [1]. We have shown previously that bradykinin provokes a depolarization preceded by a transient hyperpolarization in NG108-15 cells, ultimately leading to the release of acetylcholine [12]. In this context, it is of great interest to note the observations which indicate that (1,4,5)IP₃ induces a marked depolarization in the ventral photoreceptors of *Limulus*, usually provoked by light [23,24]. The precise role of these two putative second messengers in the physiological functions of NG108-15 cells remain to be clarified. Studies

using Quin-2 on Ca²⁺ mobilisation in the bradykinin-stimulated NG108-15 cells are currently under investigation in our laboratory.

Bradykinin has emerged as a potential neurotransmitter in the central nervous system [25], and a recent work by Perry and Snyder [26] substantiated the presence of bradykinin in mammalian brain, especially in a higher quantity in hypothalamus. Whether the action of bradykinin observed in the neuron-like cell line NG108-15 reflects the events occurring in the central nervous system awaits further exploration.

ACKNOWLEDGEMENT

This work was supported in part by a research grant from the Ministry of Education, Culture and Science, Japan.

REFERENCES

- [1] Berridge, M.J. and Irvine, R.F. (1984) *Nature* 312, 315-321.
- [2] Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U. and Nishizuka, Y. (1980) *J. Biol. Chem.* 255, 2273-2276.
- [3] Streb, H., Irvine, R.F., Berridge, M.J. and Shulz, I. (1983) *Nature* 306, 67-69.
- [4] Joseph, S.K., Thomas, A.P., Williams, R.J., Irvine, R.F. and Williamson, J.R. (1984) *J. Biol. Chem.* 259, 3077-3081.
- [5] Prentki, M., Biden, T.J., Janjic, D., Irvine, R.F., Berridge, M.J. and Wollheim, C.B. (1984) *Nature* 312, 562-564.
- [6] Irvine, R.F., Brown, K.D. and Berridge, M.J. (1984) *Biochem. J.* 222, 269-272.
- [7] Gershengorn, M.C., Geras, E., Purrello, V.S. and Rebecchi, M.J. (1984) *J. Biol. Chem.* 259, 10675-10681.
- [8] Hirata, M., Suematsu, E., Hashimoto, T., Hamachi, T. and Koka, T. (1984) *Biochem. J.* 223, 229-236.
- [9] Burgess, G.M., McKinney, J.S., Irvine, R.F., Berridge, M.J., Hoyle, P.C. and Putney, jr J.W. (1984) *FEBS Lett.* 176, 193-196.
- [10] Berridge, M.J. (1984) *Biochem. J.* 220, 345-360.
- [11] Nishizuka, Y. (1984) *Science* 225, 1365-1370.
- [12] Yano, K., Higashida, H., Inoue, R. and Nozawa, Y. (1984) *J. Biol. Chem.* 259, 10201-10207.
- [13] Downes, P. and Michell, R.H. (1982) *Cell Calcium* 3, 467-502.

- [14] MacDermot, J., Higashida, H., Wilson, S.P., Matsuzawa, H., Minna, J. and Nirenberg, M. (1979) *Proc. Natl. Acad. Sci. USA* 76, 1135-1139.
- [15] Higashida, H., Kato, T., Kano-Tanaka, K., Okuya, M., Miyake, A. and Tanaka, T. (1981) *Brain Res.* 214, 287-299.
- [16] Hallcher, L.M. and Sherman, W.R. (1980) *J. Biol. Chem.* 255, 10896-10901.
- [17] Berridge, M.J., Downes, C.P. and Hanley, M.R. (1982) *Biochem. J.* 206, 587-595.
- [18] Bone, E.A., Fretten, P., Palmer, S., Kirk, C.J. and Michell, R.H. (1984) *Biochem. J.* 221, 803-811.
- [19] Berridge, M.J., Dawson, R.M.C., Downes, C.P., Heslop, J.P. and Irvine, R.F. (1983) *Biochem. J.* 212, 473-482.
- [20] Watson, S.P., McConnell, R.T. and Lapetina, E.G. (1984) *J. Biol. Chem.* 259, 13199-13202.
- [21] Storey, D.J., Shears, S.B., Kirk, C.J. and Michell, R.H. (1984) *Nature* 312, 374-376.
- [22] Seyfred, M.A., Farrell, L.E. and Wells, W.W. (1984) *J. Biol. Chem.* 259, 13204-13208.
- [23] Fein, A., Payne, R., Corson, D.W., Berridge, M.J. and Irvine, R.F. (1984) *Nature* 311, 157-160.
- [24] Brown, J.E., Rubin, L.J., Ghalayini, A.J., Tarver, A.P., Irvine, R.F., Berridge, M.J. and Anderson, R.E. (1984) *Nature* 311, 160-163.
- [25] Snyder, S.H. (1980) *Science* 209, 976-983.
- [26] Perry, D.C. and Snyder, S.H. (1984) *J. Neurochem.* 43, 1072-1080.